Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use

A possible platform that has been authorized for use against the SARS-CoV-2 and Ebola viruses is the viral vector. NDV has been intensively researched for its oncolytic potentials, but because of its safety, immunogenicity, thermostability, and capacity to produce a variety of antigens directed against both veterinary and human diseases, it can also be an excellent choice for a viral vaccine vector. NDV-vectored vaccine candidates have been developed for a range of pathogens, including HIV, EBOV, and predominantly respiratory viruses such as influenza, SARS-CoV, SARS-CoV-2, and the Avian Influenza virus. Moreover, genetically modified chimeric NDVs that alter surface antigens can be used as potential vectors for animal disease vaccines. Nevertheless, there are several shortcomings in the large-scale production of NDV vector viruses. The NDV vector vaccine is commonly manufactured in embryonated chicken eggs and cell lines. More than ever, it is crucial to close the gaps in the process development of NDV-vectored vaccines for humans by evaluating and perfecting scalable NDV manufacturing techniques employing cell culture in bioreactors.

(MMR)